CompletedPhase 3

Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo

United States753 participantsStarted 2017-03-29

Plain-language summary

The purpose of this study is to determine if an investigational treatment is effective compared with placebo and PVP-Iodine in the treatment of adults and children with bacterial conjunctivitis.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Report presence of signs and/or symptoms of bacterial conjunctivitis for less than or equal to (\<=) 4 days prior to Visit 1
✓. Bulbar conjunctival injection: a grade of \>= 1 on 0-4 scale of Bulbar Conjunctival Injection Scale
✓. Ocular conjunctival discharge: a grade of \>= 1 (mild) on a 0-3 scale of Ocular Conjunctival Discharge Scale

Exclusion criteria

✕. Have used an investigational product or device, or
✕. Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored study.

What they're measuring

Number of Participants With Clinical Resolution Among Who Received SHP640 or Placebo on Day 5

Timeframe: Day 5

Trial details

NCT IDNCT03004924

SponsorShire

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-10-01

Results submitted2019-09-24

View on ClinicalTrials.gov More Bacterial Conjunctivitis trials